X4 Pharmaceuticals, Inc — Director's Dealing 2019

Apr 27, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2019-04-24

Reporting Person: Kelley Lynne E (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-04-24	Stock Option (right to buy)	$20.30	A	37170	Acquired	2029-04-24	Common Stock (37170)	Direct

Footnotes

F1: 25% of the shares subject to the option shall vest on April 24, 2020, with the remainder vesting in equal installments of 2.083% of the shares subject to the option on the last day of each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.